# Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients

> **NCT02440230** · PHASE2 · COMPLETED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 110 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** OFS + Anastrozole
- **DRUG:** OFS + Exemestane

## Key facts

- **NCT ID:** NCT02440230
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02440230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02440230, "Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02440230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*